ASH 2016: Hemato-oncologie Journaal 1


December 15, 2016

  • Deel deze pagina:

In het eerste Hemato-oncologie Journaal vanaf de 58e ASH Annual Meeting bespreken we de belangrijkste presentaties van 4 en 5 december over lymfomen.

Ook kunt u kijken naar twee studietuinen over leukemie bij kinderen.

Gasten:

  • Dr. Elly Lugtenburg, Erasmus MC Rotterdam
  • Dr. Jeanette Doorduijn, Erasmus MC Rotterdam

Presentatie: Inge Diepman

Onderwerpen:

1elijns behandeling DLBCL

  • 469 Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303
  • 470 Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)


Lenalomide maintenance bij DLBCL

  • 471 First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa


Rituximab onderhoud bij MCL

  • 145 Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group


Obinutuzumab bij RR-NHL

  • 615 Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study


Studietuinen:

Drs. Kim Klein, VUMC Amsterdam

  • 2896 The Prognostic Impact of Cytogenetics and Karyotype Changes in Pediatric Patients with Relapsed Acute Myeloid Leukemia: A Retrospective Cohort Study within the Relapsed AML 2001/01 Study


Drs. Željko Antić, Prinses Máxima Centrum Utrecht

  • 4072 Genomic Architecture and Clonal Dynamics of Early Relapsed BCP-ALL


Dit programma wordt financieel mogelijk gemaakt door Novartis, BMS en Janssen

Gerelateerde artikelen